Identifying emerging novel metastatic castration-resistant prostate cancer therapies; understanding PARPi in combination with AR-targeted treatments

Agenda:

Expert Talk 1: Patient Selection For PARP Inhibitor: Genomic Considerations

Pedro Barata

*Tulane Medical School Department of Internal Medicine, New Orleans, Louisiana,USA.

Expert Talk 2: Importance of Genomics in Prostate Cancer: Role of PARPi in CRPC

Jorge A. Garcia

*Oncology University Hospitals Seidman Cancer Center, Cleveland, OH, USA.

Expert Talk 3: Prostate Cancer PARP Combination Clinical Trials

Elisabeth Heath

*Karmanos Cancer Institute, Wayne State School of Medicine, Detroit, Michigan.

Expert Panel Discussion and Questions & Answers

Panelists: Pedro Barata, Jorge A. Garcia and Elisabeth Heath

Tulane Medical School Department of Internal Medicine, New Orleans, Louisiana,USA., Oncology University Hospitals Seidman Cancer Center, Cleveland, OH, USA. & *Karmanos Cancer Institute, Wayne State School of Medicine, Detroit, Michigan.

Learning Objectives:

After completing the independent medical educational activity, learners will be able to:

a. Explain mechanisms of action and risks associated with PARPi alone, as well as in combination with AR inhibitors currently used in practice.

b. Identify and list gene mutations that are predictive biomarkers to identify PARPi + AR inhibitors- responding mCRPC patients.

c. Explain the rationale flow in deciphering when it is finally appropriate to have a mCRPC patient put on a PARPi + AR inhibitor combination treatment.

d. Describe the current landscape of clinical trials that involve the combination of PARPI + AR inhibitor to treat mCRPC.

Certificate of attendance: The certificates will be given to those attendees who will complete pre & post symposium evaluation quiz.

Conflict of interests: No known conflict of interests

Acknowledgment: This symposium is supported by a research grant from Astellas pharma.